FDA Approves Trastuzumab Deruxtecan for Certain Patients With HER2-Positive Metastatic Breast Cancer
May 5th 2022Trastuzumab deruxtecan (Enhertu) approved for adult patients with unresectable or metastatic HER2-positive breast cancer who were previously administered an anti–HER2-based regimen.
Read More
Assessing State, Federal Legislation Alignment With Expansion of Pharmacist’s Role on Care Team
May 4th 2022Tracy Russell, senior director, State Government Affairs at CoverMyMeds, discusses her presentation at Asembia Summit 2022 on legislation aligned with the movement to expand the pharmacist’s role on the care team.
Watch
Expert: Specialty Approvals Pharmacists Should Look for on the Horizon
May 4th 2022Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, addresses his presentation on the specialty pharmaceutical pipeline, and specifically what approvals pharmacists should look for on the horizon.
Watch
Darolutamide/Docetaxel Granted FDA Priority Review for Metastatic Hormone-Sensitive Prostate Cancer
May 4th 2022Trials results show darolutamide, docetaxel, and androgen deprivation therapy (ADT) reduced the risk of death by 32.5% versus docetaxel/ADT in patients with metastatic hormone-sensitive prostate cancer.
Read More
Learning in Lockdown: Adapting a Reproductive Health Campaign for Pandemic Life
Although COVID-19 paused our original plans, we were ultimately able to reach more people than we ever could have via in-person presentations alone.
Read More
Overview of the Most Significant Drugs in Specialty Pharmacy FDA Pipeline in 2022
May 3rd 2022Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, discusses some of the more significant drugs for specialty pharmacy in the FDA pipeline this year.
Watch